Loading
Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance.
Jennifer Woyach was principal investigator of Alliance A041202, the trial showing ibrutinib with or without rituximab beats bendamustine-rituximab in older patients with untreated CLL and ending chemoimmunotherapy for this group, and first author of the study identifying BTK C481S and PLCG2 mutations as the mechanisms of ibrutinib resistance. She chairs the Alliance CLL committee and leads trials of fixed-duration combinations.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
Shares The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
Shares Chronic lymphocytic leukaemia and the tag cll.